Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Malignant Neoplasm in the Brain: early-phase trial registry
18 of 44 indexed Metastatic Malignant Neoplasm in the Brain trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #330 of 28,707 conditions by registered trial count.
44 US clinical trials · 18 currently recruiting · #330 of 28,707 conditions by registered trial count
Metastatic Malignant Neoplasm in the Brain: 44 US clinical trials tracked, 18 recruiting.
Metastatic Malignant Neoplasm in the Brain is the subject of 44 registered US clinical trials on ClinicalTrials.gov, 18 of them currently open to new participants. 10 are in Phase 3-4 (later-stage) and 25 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 13 of these trials.
Enrollment posture brief
Registry condition metastatic-malignant-neoplasm-in-the-brain
OPEN 18 | RECR 41% | LATE 10 | EARLY 25 | RANK #330 | SPON 13
Volume-matched condition peers
Nearest open-share peer: Brain Injuries, Traumatic (41% recruiting · 22 trials)
Metastatic Malignant Neoplasm in the Brain lists 18 open slots (41% of 44 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Malignant Neoplasm in the Brain on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Malignant Neoplasm in the Brain recruits in line with its size-band peers.
18 of 44 indexed trials (40.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Metastatic Malignant Neoplasm in the Brain research.
M.D. Anderson Cancer Center accounts for 13 of 44 trials (29.5%). 14 distinct sponsors appear on at least one study for this condition label.
-
Most Metastatic Malignant Neoplasm in the Brain trials plan to enrol fewer than 100 people.
Median target enrolment is 54 among the 44 trials that report a genuine target (sentinel values excluded). 30 of those (68.2%) plan for fewer than 100 participants.
-
Metastatic Malignant Neoplasm in the Brain research is mostly interventional.
42 interventional and 2 observational studies make up this index (95.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
44 total, page 1 of 1
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
SWOG Cancer Research Network
NCT03418961
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NRG Oncology
NCT06500455
Patient Perceptions Around Quality of Care Through Telemedicine in Neuro-Oncology
M.D. Anderson Cancer Center
NCT04988009
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability
NRG Oncology
NCT04804644
Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases
M.D. Anderson Cancer Center
NCT03741673
Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System
OHSU Knight Cancer Institute
NCT03270059
Pre-Operative or Post-Operative Stereotactic Radiosurgery in Treating Patients With Operative Metastatic Brain Tumors
Mayo Clinic
NCT03750227
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
SWOG Cancer Research Network
NCT04511013
Feasibility of Intraoperative Microdialysis During Neurosurgery for Central Nervous System Malignancies
Mayo Clinic
NCT04047264
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT03184038
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
M.D. Anderson Cancer Center
NCT02754544
SRS Compared With FSRS for Treatment of Intact Metastatic Brain Disease, FRACTIONATE Trial
Mayo Clinic
NCT05222620
Advanced Magnetic Resonance Imaging for the Identification of Recurrent Brain Tumors and Radiation Necrosis
Jonsson Comprehensive Cancer Center
NCT07339085
Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain
Kari Kendra
NCT05588453
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
Roswell Park Cancer Institute
NCT04348747
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
Jonsson Comprehensive Cancer Center
NCT06650163
An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis
City of Hope Medical Center
NCT05376878
Arginine and Whole Brain Radiation Therapy for the Treatment of Patients With Brain Metastases
Emory University
NCT06328686
Single Fraction Stereotactic Radiosurgery Compared With Fractionated Stereotactic Radiosurgery in Treating Patients With Resected Metastatic Brain Disease
Alliance for Clinical Trials in Oncology
NCT04114981
Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases
NRG Oncology
NCT05438212
Stereotactic Radiosurgery Compared to Observation in Treating Patients With Brain Metastases
M.D. Anderson Cancer Center
NCT00950001
Neuropsychological Care for Maintaining Quality of Life After Radiation Therapy in Patients With Brain Metastases
Ohio State University Comprehensive Cancer Center
NCT05503251
Stereotactic Radiosurgery or Whole Brain Radiation Therapy in Treating Patients With Newly Diagnosed Non-melanoma Brain Metastases
M.D. Anderson Cancer Center
NCT01592968
Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
NCT02696993
Mind-Body Intervention in Glioma Couples
M.D. Anderson Cancer Center
NCT03244995
Stereotactic Radiosurgery for the Treatment of Patients With Small Cell Lung Cancer Brain Metastasis
M.D. Anderson Cancer Center
NCT04516070
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
M.D. Anderson Cancer Center
NCT02910700
Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain Metastases
M.D. Anderson Cancer Center
NCT01644591
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
SWOG Cancer Research Network
NCT04647916
Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases
M.D. Anderson Cancer Center
NCT03175432
Radiosurgery Before Surgery for the Treatment of Brain Metastases
Emory University
NCT04895592
Low Dose Versus Standard Dose Dexamethasone for Reduction of Swelling in Patients with Primary or Metastatic Brain Tumors
City of Hope Medical Center
NCT05139043
HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases
City of Hope Medical Center
NCT03696030
Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT04250545
nTMS in Planning Stereotactic Radiosurgery in Patients With Brain Metastases in the Motor Cortex
M.D. Anderson Cancer Center
NCT04062305
Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors
National Cancer Institute (NCI)
NCT02589522
Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
National Cancer Institute (NCI)
NCT02993146
Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
National Cancer Institute (NCI)
NCT02015117
Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
National Cancer Institute (NCI)
NCT02971501
Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases
Emory University
NCT05341349
Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases
OHSU Knight Cancer Institute
NCT00103038
Blood Brain Barrier Differences in Patients with Brain Tumors Undergoing Surgery
Mayo Clinic
NCT03071913
STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain
M.D. Anderson Cancer Center
NCT01904123
Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread
National Cancer Institute (NCI)
NCT04631029
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 13 |
| Phase 2 | 12 |
| Phase 3 | 9 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Malignant Neoplasm in the Brain records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Malignant Neoplasm in the Brain trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Malignant Neoplasm in the Brain page
44 registered trials, 18 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 18 Metastatic Malignant Neoplasm in the Brain trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Metastatic Malignant Neoplasm in the Brain trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Malignant Neoplasm in the Brain condition card totals 44 registered trials; most-linked intervention Stereotactic Radiosurgery; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.